Immunovant, Inc. shared six-month off-treatment data in uncontrolled Graves' disease patients treated with batoclimab, showing promising results.
~80% of patients maintained normal thyroid function after the six-month follow-up period, with significant remission rates.
Two registrational trials for IMVT-1402 in Graves' disease are currently enrolling, with outcomes expected in 2027.
Response Rate
~80% of patients demonstrated response with normal thyroid function after six-month off-treatment period.
ATD-Free Remission
~50% of responders achieved anti-thyroid drug (ATD) free remission after six months following batoclimab treatment.
Study Design
Batoclimab, a fully human monoclonal antibody targeting FcRn, showed potential disease-modifying effects in uncontrolled Graves' disease patients.
Safety Profile
Safety and tolerability of batoclimab were consistent with prior studies, indicating a favorable profile.
Trials Enrollment
Two global trials for IMVT-1402 in Graves' disease are ongoing, with topline results expected in 2027.
- The six-month remission data suggests a potential paradigm shift in the treatment of Graves' disease, offering hope for patients with uncontrolled conditions.
- The durability of response and the achievement of ATD-free remission highlight the clinical significance of batoclimab in addressing the unmet needs of Graves' disease patients.
The data presented by Immunovant demonstrate promising outcomes in the treatment of Graves' disease, paving the way for future advancements in autoimmune disease therapy.